KD Pharma Strengthens Its Technology Platform by Acquiring UK Manufacturing Site

Acquisition allows KD Pharma to further expand its leading position
in the omega-3 pharmaceutical market

BIOGGIO, Switzerland–(BUSINESS WIRE)–KD Pharma Group SA announced that it has acquired a manufacturing site
in Seal Sands, United Kingdom. The KD Pharma UK LTD entity will expand
KD Pharma’s capacity for manufacturing omega-3-based intermediates used
in producing active pharmaceutical ingredients (APIs). The site was
previously used for manufacturing omega-3 products.

“This acquisition expands our technology and manufacturing base for
producing APIs with the highest concentrations of EPA and DHA omega-3s,”
said Oscar Groet, KD Pharma Group’s Chief Executive Officer. “The
breadth of our technology platform sets KD Pharma apart, no company has
more technologies for isolating and fractionating lipids,” he concluded.

KD Pharma Group strives to be the leading manufacturer in the rapidly
growing omega-3 API market. The UK acquisition will enable it to meet
market demand for the highest quality APIs in response to new product
approvals, label expansions, and supportive clinical research. The
company says the site will be brought online this year and operated
alongside KD Pharma Group’s other manufacturing sites in Bexbach,
Germany; Brattvag, Norway; and Miami, United States.

About the KD Pharma Group SA

The KD Pharma Group is the third largest Omega-3 producer in the world
with 400 people and 7 sites located in the UK, Norway, Germany and the
US. The company concentrates nutraceutical and pharmaceutical oils and
makes customized finished products for its customers in soft gel capsule
and bottled liquid forms. The KD Pharma Group has the global reach,
technology and vertical integration necessary to develop customized
Omega-3 products with complete supply chain efficiency for our
customers. Visit KDPharmaGroup.com
to learn more.

Contacts

Adam Ismail
Chief Strategy Officer
KD Pharma Group
+1
(385) 237-2787
[email protected]